SCHEMBL7666277

SCHEMBL7666277

COc1ccccc1N1C(C)N(c2cccnc2)C(=O)C12CCN(C(=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1)CC2

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 10/20 0.47
USP2 O75604 6/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
ALDH1A1 P00352 4/20 0.46
TACR1 P25103 2/20 0.44
CYP3A4 P08684 9/20 0.44
HIF1A Q16665 4/20 0.44
HSD17B10 Q99714 2/20 0.43
CYP2D6 P10635 4/20 0.42
CYP1A2 P05177 3/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42
MAPK1 P28482 1/20 0.42
CYP2C9 P11712 3/20 0.42
HTR1A P08908 1/20 0.41
ADRA1D P25100 1/20 0.41
ADRA1A P35348 1/20 0.41
ADRA1B P35368 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7675223 0.90 CYP3A4 (0.45) TSHRUSP2SMN1; SMN2ALDH1A1TACR1
SCHEMBL5558342 0.89 CYP3A4 (0.44) TSHRUSP2SMN1; SMN2ALDH1A1TACR1
SCHEMBL5559720 0.89 CYP3A4 (0.51) TSHRUSP2SMN1; SMN2ALDH1A1TACR1
SCHEMBL5557665 0.81 CYP3A4 (0.56) TSHRUSP2SMN1; SMN2ALDH1A1TACR1
SCHEMBL5553280 0.81 CYP3A4 (0.52) TSHRUSP2SMN1; SMN2ALDH1A1TACR1
SCHEMBL5558456 0.78 TSHR (0.58) TSHRUSP2SMN1; SMN2ALDH1A1TACR1
SCHEMBL7666272 0.77 USP2 (0.50) TSHRUSP2SMN1; SMN2ALDH1A1TACR1
SCHEMBL5553120 0.76 DDR1 (0.49) TSHRUSP2SMN1; SMN2ALDH1A1TACR1
SCHEMBL5557471 0.74 CYP3A4 (0.59) TSHRUSP2SMN1; SMN2TACR1CYP3A4
SCHEMBL5557466 0.74 USP2 (0.55) TSHRUSP2SMN1; SMN2ALDH1A1TACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020006932-A1 Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor F. HOFFMANN-LA ROCHE AG (CH) 2002-01-17 US claimed
US-6482829-B2 CENTRAL NERVOUS SYSTEM DISORDERS; HEEADACHES, ANTIINFLAMMATORY AGENTS HOFFMANN-LA ROCHE INC. 2002-11-19 US disclosed
US-20020006932-A1 Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor F. HOFFMANN-LA ROCHE AG (CH) 2002-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020006932-A1 Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor TACR1, TACR2, NPR1 TSHR 232/4885USP2 3849/4885SMN1; SMN2 1717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.